GGHC
LGND icon

Gilder Gagnon Howe & Co’s Ligand Pharmaceuticals LGND Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-25,454
Closed -$989K – 305
2014
Q2 		$989K Sell
25,454
-386,371
-94% -$15.7M 0.01% 223
2014
Q1 		$17.3M Buy
411,825
+5,497
+1% +$229K 0.24% 97
2013
Q4 		$13.3M Buy
406,328
+127,436
+46% +$4.15M 0.19% 101
2013
Q3 		$7.53M Buy
278,892
+141,765
+103% +$3.99M 0.12% 122
2013
Q2 		$3.2M Buy
+137,127
New +$2.47M 0.06% 168

Other funds holding LGND

RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gilder Gagnon Howe & Co's LGND Position: Q3 2014 in Review

Gilder Gagnon Howe & Co sold out of Ligand Pharmaceuticals (LGND) in Q3 2014, closing a stake of 25,454 shares — an estimated $989K sold.

Gilder Gagnon Howe & Co first reported a position in LGND in Q2 2013 and held it in 5 quarters. The position peaked at $17.3M in Q1 2014. 174 funds tracked by Wall St. Rank hold LGND as of Q3 2014.

  • Gilder Gagnon Howe & Co reported no remaining Ligand Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 25,454 Ligand Pharmaceuticals shares in Q3 2014, an estimated $989K.
  • Gilder Gagnon Howe & Co first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Gilder Gagnon Howe & Co's Ligand Pharmaceuticals position peaked at $17.3M in Q1 2014.
  • 174 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2014.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2014, filed 13 Nov 2014.